Pharmacogenetics of Efavirenz Discontinuation for Reported Central Nervous System Symptoms Appears to Differ by Race

BACKGROUND: Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation. METHODS: Patients had initiated efavirenz-containing regimens at an HIV primary care clinic in th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacogenet Genomics
Hlavní autoři: Leger, Paul, Chirwa, Sanika, Turner, Megan, Richardson, Danielle M., Baker, Paxton, Leonard, Michael, Erdem, Husamettin, Olson, Lana, Haas, David W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5014672/
https://ncbi.nlm.nih.gov/pubmed/27509478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000238
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky